R&D

R&D

Cobimetinib

Tinibs

Oncology
Futibatinib
Fedratinib
Momelotinib
Pemigatinib
Olutasidenib
Quizartinib
Ruxolitinib
Regorafenib
Talazoparib
Trametinib
Upadacitinib
Vorasidenib
Zanubrutinib